Greek drug price cuts will have knock on effects across Europe, industry warnsBMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c3043 (Published 08 June 2010) Cite this as: BMJ 2010;340:c3043
- Rory Watson
The European drug industry has warned that the Greek government’s decision to reduce what it is prepared to pay for certain medicines by up to 27% will have a detrimental impact not only in Greece but elsewhere in Europe.
The warning by the European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the research based drug industry in Europe, follows the decision by two Danish companies to withdraw some of their products from the Greek market.
The federation notes that the reduction in prices “will inevitably raise the likelihood of increased parallel exports of medicinal products from Greece, diverting supplies needed …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial